These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks identifies Regeneron and Danaher as potential earnings-surprise candidates ahead of their October 30 and October 21, 2026 reports, respectively. Regeneron's Most Accurate Estimate is $15.96 per share versus $15.93 consensus (Earnings ESP +0.23%); Danaher's is $1.93 versus $1.92 (+0.30%). Zacks says stocks combining a #3-or-better rank with positive ESP produced positive surprises 70% of the time in its analysis; the article reports no actual earnings results or market reaction.

Analysis

The signal is too small to underwrite a pre-earnings position on its own: these are marginal estimate gaps, not evidence of broad or material upward revisions. The cited backtest is promotional absent details on sample construction, transaction costs, and drawdowns; a historical hit rate is not the probability of a tradable post-report gain. The key distinction is whether revisions are broad-based and supported by operating indicators, versus a narrow estimate change that the market has already absorbed.

Near term, DHR’s earlier report is the cleaner test of whether its estimate revisions reflect improving demand across life-sciences tools and diagnostics; weakness in order trends or guidance could pressure the wider tools group even if quarterly EPS clears. For REGN, an EPS beat without supportive product-level sales or forward commentary may not overcome concerns about durability and competitive substitution. Verify revenue, guidance, and revision breadth rather than reacting to the headline beat.

Over the next 1–3 months, guidance and subsequent estimate revisions matter more than this screen. A broad, sustained upward revision cycle could support relative performance; a one-quarter beat with unchanged or weaker forward estimates risks a fade. No structural conclusion is justified from this article alone. Falsify any bullish read if either company misses revenue expectations, lowers forward guidance, or reports operating trends inconsistent with the beat.

Key Decisions for Investors

• Do not buy either stock solely on the positive ESP screen. Before DHR’s October 21 report and REGN’s October 30 report, check the number and direction of recent estimate revisions, revenue estimates, and available operating indicators; absent corroboration, stay flat into the events.
• If revisions broaden and operating data confirm the trend, consider a small, defined-risk post-report position rather than pre-event exposure. For DHR, require constructive forward demand commentary; for REGN, require product-level revenue support and credible forward guidance. Size against the possibility that a modest EPS beat is already priced in.
• Watch the first post-report reaction and the next analyst revision cycle over 1–3 months. A beat followed by flat-to-lower forward estimates, weak revenue, or a negative guidance response falsifies the bullish thesis; avoid extrapolating a single quarter into a durable earnings inflection.